Part D coverage gap and adherence to diabetes medications

American Journal of Managed Care

Volumn 16, Issue 12, 2010, Pages 911-918

  Gu, Qian ^a   Zeng, Feng ^b   Patel, Bimal V ^b   Tripoli, Louis C ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b MedImpact Healthcare Systems Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; COHORT ANALYSIS; CONFIDENCE INTERVAL; DIABETES MELLITUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK;

AGED; COHORT STUDIES; CONFIDENCE INTERVALS; DIABETES MELLITUS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEALTH SERVICES ACCESSIBILITY; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; INSURANCE CLAIM REVIEW; INSURANCE COVERAGE; MALE; MEDICARE PART D; MEDICATION ADHERENCE; METFORMIN; ODDS RATIO; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; UNITED STATES;

EID: 78650960645     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Joyce GF, Goldman DP, Karaca-Mandic P, Zheng Y. Pharmacy benefit caps and the chronically ill. Health Aff (Millwood). 2007;26(5):1333-1344.
2. Hsu J, Price M, Huang J, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med. 2006;354(22):2349-2359.
3. Sun SX, Lee KY, Aruru M. Examining Part D beneficiaries' medication use in the doughnut hole. Am J Pharm Benefits. 2009;1(1):19-28.
4. Zhang Y, Donohue JM, Newhouse JP, Lave JR. The effects of the coverage gap on drug spending: a closer look at Medicare Part D. Health Aff (Millwood). 2009;28(2):w317-w325.
5. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007. http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2007.pdf. Accessed October 7, 2009.
6. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007 [published correction appears in Diabetes Care. 2008; 31(6):1271]. Diabetes Care. 2008;31(3):596-615.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354(9178):602]. Lancet 1998:352(9131):837- 853.
8. Stephens JM, Botteman MF, Hay JW. Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of literature. J Manag Care Pharm. 2006;12(2):130-142.
9. Shetty S, Secnik K, Oglesby AK. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. J Manag Care Pharm. 2005;11(7):559-564.
10. Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care. 2004;27(12):2800-2805.
11. Krapek K, King K, Warren SS, et al. Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother. 2004; 38(9):1357-1362.
12. Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care. 2002;25(6):1015-1021.
13. Dalewitz J, Khan N, Hershey CO. Barriers to control blood glucose in diabetes mellitus. Am J Med Qual. 2000;15(1):16-25.
14. Hepke KL, Martus MT, Share DA. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care. 2004;10(2 pt 2):144-151.
15. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherent on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166(17):1836-1841.
16. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care. 2004;27(9):2149-2153.
17. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218-1224.
18. Odegard PS, Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ. 2007;33(6):1014-1029.
19. Fishman PA, Goodman MJ, Hornbrook MC, Meenan RT, Bachman DJ, O'Keeffe Rosetti MC. Risk adjustment using automated ambulatory pharmacy data: the RxRisk model. Med Care. 2003;41(1):84-99.
20. Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ. Impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050. Diabetes Care. 2006;29(9):2114-2116.
21. DM, Holman RR, Buse JB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
22. Patient Protection and Affordable Care Act. HR 3590. Pub L No. 111-148.124 Stat 119.